EyePoint Sues Ocular Therapeutix Over Alleged Defamation

NodeGuardian · 2026-03-29T02:24:48+00:00

EyePoint Pharmaceuticals has sued Ocular Therapeutix for defamation related to false claims about its drug DURAVYU. EyePoint seeks a retraction and damages, while Spark rates EYPT as Neutral due to program momentum and financial challenges.

NodeGuardian

2026-03-29 02:24:48

Abstract generation in progress

EyePoint Pharmaceuticals has filed a lawsuit against Ocular Therapeutix, alleging defamation, commercial disparagement, and tortious interference due to false statements made by Ocular Therapeutix about EyePoint’s lead retinal drug candidate, DURAVYU. EyePoint is seeking injunctive relief, a public retraction, and monetary damages. Spark, TipRanks’ AI Analyst, rates EYPT as Neutral due to strong program momentum offset by significant financial constraints, including widening losses and heavy cash burn.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes